12 Best Multibagger Stocks to Invest In According to Billionaires

10. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)

Dollar Value of Billionaire Holdings: $1.39 million

Number of Billionaire Investors: 24

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is one of the best multibagger stocks to invest in according to billionaires. On February 5, Arrowhead Pharmaceuticals achieved a strategic turning point in FQ1 2026, transitioning into a commercial-stage organization following the US FDA approval of its first medicine, REDEMPLO (plozasiran). This siRNA therapeutic, designed to treat familial chylomicronemia syndrome/FCS, also received regulatory clearances in China and Canada.

The US launch has shown early momentum with over 100 initial prescriptions and the establishment of a dedicated patient support program, marking a major milestone in the company’s history. The company’s research and development pipeline reached several technical landmarks, highlighted by the initiation of a Phase 1/2a trial for ARO-DIMER-PA, the industry’s first dual-function clinical candidate to target two genes in one molecule. Additionally, Arrowhead reported encouraging interim data from its obesity programs, where ARO-INHBE showed a significant weight loss advantage when combined with tirzepatide. The firm also advanced its CNS efforts by dosing the first subjects in a trial for ARO-MAPT, which uses a new delivery system capable of crossing the blood-brain barrier.

Financially, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) swung to a net income of $30.8 million for the quarter, a sharp contrast to the $173.1 million loss in the prior year period. This profitability was driven by a surge in revenue to $264 million, fueled by a $200 million upfront payment from a new global collaboration with Novartis and a $200 million milestone from Sarepta Therapeutics.

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) develops medicines for the treatment of intractable diseases in the US. Its pipeline primarily includes Plozasiran, Zodasiran, ARO-DIMER-PA, and ARO-PNPLA3.